Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02146222 · ClinicalTrials.gov registry record · Phase 1
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT02146222: Completed Phase 1 study, sponsored by University of Wisconsin, Madison.
NCT02146222 is a Phase 1 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02146222, a Phase 1 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This partially randomized phase I trial studies the side effects and how well sequential dosing of vascular endothelial growth factor receptor (VEGFR)/platelet derived growth factor receptor (PDGFR) dual kinase inhibitor X-82 and docetaxel works in treating patients with solid tumors. VEGFR/PDGFR dual kinase inhibitor X-82 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving VEGFR/PDGFR dual kinase inhibitor X-82 and docetaxel one at a time instead of concurrently may work in treating patients with solid tumors.
Primary Outcome
The number and severity of toxicities and adverse events will be summarized using frequencies and percentages and stratified by X-82 dose level (low or high) and treatment (X-82 alone or X-82/docetaxel). Ninety-five percent confidence intervals for the toxicity rates will be constructed.
Interventions
- DRUG docetaxel
- OTHER pharmacological study
- OTHER fluorine F 18 fluorothymidine
- PROCEDURE positron emission tomography/computed tomography
- DRUG VEGFR/PDGFR dual kinase inhibitor X-82
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2014-09 |
| Est. Completion | 2016-12 |
| Phase | Phase 1 |
What the finished NCT02146222 record still lists
NCT02146222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 5 interventions - of which docetaxel is the first listed.
NCT02146222 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02146222 about?
NCT02146222 is a clinical study titled "VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors". This partially randomized phase I trial studies the side effects and how well sequential dosing of vascular endothelial growth factor receptor (VEGFR)/platelet derived growth factor receptor (PDGFR) dual kinase inhibitor X-82 and docetaxel works in treating patients with solid tumors. VEGFR/PDGFR du...
What is the current status of trial NCT02146222?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2014-09. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02146222?
The interventions under investigation include: docetaxel (DRUG), pharmacological study (OTHER), fluorine F 18 fluorothymidine (OTHER), positron emission tomography/computed tomography (PROCEDURE), VEGFR/PDGFR dual kinase inhibitor X-82 (DRUG).
Who is sponsoring clinical trial NCT02146222?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02146222's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia